Competitive Repopulation and Allo-Immunologic Pressure Determine Chimerism Kinetics after T Cell-Depleted Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion.

Acute lymphoblastic leukemia Acute myeloid leukemia Allogeneic stem cell transplantation Chimerism Donor lymphocyte infusion Graft-versus-host disease T cell depletion

Journal

Transplantation and cellular therapy
ISSN: 2666-6367
Titre abrégé: Transplant Cell Ther
Pays: United States
ID NLM: 101774629

Informations de publication

Date de publication:
04 2023
Historique:
received: 13 10 2022
revised: 12 12 2022
accepted: 26 12 2022
medline: 28 3 2023
pubmed: 2 1 2023
entrez: 1 1 2023
Statut: ppublish

Résumé

After allogeneic stem cell transplantation (alloSCT), patient-derived stem cells that survived the pretransplantation conditioning compete with engrafting donor stem cells for bone marrow (BM) repopulation. In addition, donor-derived alloreactive T cells present in the stem cell product may favor establishment of complete donor-derived hematopoiesis by eliminating patient-derived lymphohematopoietic cells. T cell-depleted alloSCT with sequential transfer of potentially alloreactive T cells by donor lymphocyte infusion (DLI) provides a unique opportunity to selectively study how competitive repopulation and allo-immunologic pressure influence lymphohematopoietic recovery. This study aimed to determine the relative contribution of competitive repopulation and donor-derived anti-recipient alloimmunologic pressure on the establishment of lymphohematopoietic chimerism after alloSCT. In this retrospective cohort study of 281 acute leukemia patients treated according to a protocol combining alemtuzumab-based T cell-depleted alloSCT with prophylactic DLI, we investigated engraftment and quantitative donor chimerism in the BM and immune cell subsets. DLI-induced increase of chimerism and development of graft-versus-host disease (GVHD) were analyzed as complementary indicators for donor-derived anti-recipient alloimmunologic pressure. Profound suppression of patient immune cells by conditioning sufficed for sustained engraftment without necessity for myeloablative conditioning or development of clinically significant GVHD. Although 61% of the patients without any DLI or GVHD showed full donor chimerism (FDC) in the BM at 6 months after alloSCT, only 24% showed FDC in the CD4

Identifiants

pubmed: 36587743
pii: S2666-6367(22)01869-3
doi: 10.1016/j.jtct.2022.12.022
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

268.e1-268.e10

Informations de copyright

Copyright © 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Auteurs

Eva A S Koster (EAS)

Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: e.a.s.koster@lumc.nl.

Peter A von dem Borne (PA)

Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.

Peter van Balen (P)

Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.

Esther H M van Egmond (EHM)

Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.

Erik W A Marijt (EWA)

Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.

Sabrina A J Veld (SAJ)

Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.

Inge Jedema (I)

Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.

Tjeerd J F Snijders (TJF)

Department of Hematology, Medisch Spectrum Twente, Enschede, The Netherlands.

Daniëlle van Lammeren (D)

Department of Hematology, HagaZiekenhuis, The Hague, The Netherlands.

Hendrik Veelken (H)

Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.

J H Frederik Falkenburg (JHF)

Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.

Liesbeth C de Wreede (LC)

Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.

Constantijn J M Halkes (CJM)

Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH